Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 2.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 2.00M | -- | -- | -- |
| Cost of Revenue | -- | 1.99M | -- | -- | -- |
| Gross Profit | -- | 13.00K | -- | -- | -- |
| SG&A Expenses | 1.46M | 2.31M | 2.13M | 847.00K | 1.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.49M | 6.50M | 3.60M | 3.09M | 3.14M |
| Operating Income | -2.49M | -4.50M | -3.60M | -3.09M | -3.14M |
| Income Before Tax | 13.13M | -7.06M | -9.78M | -18.51M | 10.84M |
| Income Tax Expenses | -126.00K | 584.00K | 416.00K | 1.13M | 1.63M |
| Earnings from Continuing Operations | 13.26M | -7.64M | -10.20M | -19.64M | 9.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 28.00K | -- | 10.00K | 23.00K | 8.00K |
| Net Income | 13.29M | -7.64M | -10.19M | -19.62M | 9.21M |
| EBIT | -2.49M | -4.50M | -3.60M | -3.09M | -3.14M |
| EBITDA | -2.46M | -4.47M | -3.56M | -3.04M | -3.08M |
| EPS Basic | 0.32 | -0.19 | -0.25 | -0.48 | 0.22 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.04 | -0.28 | -0.03 |
| EPS Diluted | 0.31 | -0.19 | -0.26 | -0.48 | 0.22 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.04 | -0.28 | -0.03 |
| Average Basic Shares Outstanding | 41.74M | 41.23M | 40.67M | 40.90M | 40.96M |
| Average Diluted Shares Outstanding | 42.61M | 41.23M | 40.67M | 40.90M | 41.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |